Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Neubauer

Showing results (551-560 of 554) with videos related to

Pageof 56
Sort By:
You have reached the last page of results.This site can display upto 554 results.
Allergy|April 28, 2015
Are allergic multimorbidities and IgE polysensitization associated with the persistence or re-occurrence of foetal type 2 signalling? The MeDALL hypothesisJ Bousquet, J M Anto, M Wickman, et al.
Leukemia|August 15, 2017
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinantsR Hehlmann, M Lauseker, S Saußele, et al.
Allergy|January 26, 2011
MeDALL (Mechanisms of the Development of ALLergy): an integrated approach from phenotypes to systems medicineJ Bousquet, J Anto, C Auffray, et al.
Medrxiv : the Preprint Server for Health Sciences|March 3, 2023
Exome sequencing of 20,979 individuals with epilepsy reveals shared and distinct ultra-rare genetic risk across disorder subtypesSiwei Chen, Bassel W Abou-Khalil, Zaid Afawi, et al.
Pageof 56

Showing results (551-560 of 554) with videos related to

Sort By:
Pageof 56
You have reached the last page of results.This site can display upto 554 results.
Allergy|April 28, 2015
Are allergic multimorbidities and IgE polysensitization associated with the persistence or re-occurrence of foetal type 2 signalling? The MeDALL hypothesisJ Bousquet, J M Anto, M Wickman, et al.
Leukemia|August 15, 2017
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinantsR Hehlmann, M Lauseker, S Saußele, et al.
Allergy|January 26, 2011
MeDALL (Mechanisms of the Development of ALLergy): an integrated approach from phenotypes to systems medicineJ Bousquet, J Anto, C Auffray, et al.
Medrxiv : the Preprint Server for Health Sciences|March 3, 2023
Exome sequencing of 20,979 individuals with epilepsy reveals shared and distinct ultra-rare genetic risk across disorder subtypesSiwei Chen, Bassel W Abou-Khalil, Zaid Afawi, et al.
Pageof 56